CD7 CAR: sword and shield

Article Oncology

Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management

Shiqi Li et al.

Summary: The study reports two cases of patients with relapsed/refractory T-ALL treated with GC027, showing robust expansion of CAR-T cells and rapid eradication of CD7(+) T lymphoblasts. Both patients achieved complete remission with no minimal residual disease. One patient remained in ongoing remission for over 1 year after CAR T-cell infusion. Grade 3 cytokine release syndrome occurred in both patients and was managed with a novel approach using ruxolitinib. No graft-versus-host disease was observed. These findings suggest that GC027 may be a promising new approach for treating refractory/relapsed T-ALL. Further studies are needed.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

Jing Pan et al.

Summary: Donor-derived anti-CD7 CAR T cells showed efficient expansion and high complete remission rate in patients with r/r T-ALL, with manageable adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Base-edited CAR T cells for combinational therapy against T cell malignancies

Christos Georgiadis et al.

Summary: The use of base editing technology allows for the generation of CAR T cells with resistance to T cell fratricide, enabling enhanced cytotoxic effects against specific targets. Co-cultured 3CAR and 7CAR cells exhibit high cytotoxicity, particularly effective against CD3 + CD7 + T-ALL targets.

LEUKEMIA (2021)

Add to Collection

Article Oncology